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Contrast Agents for Hepatic Magnetic Resonance Imaging
Giovanni Morana, M.D., Luigi Grazioli, M.D., Marco Testoni, M.D., Paolo Caccia, M.D., and
Carlo Procacci, M.D.
Summary: The current availability of liver-specific contrast media (LSCM) allows the
possibility to obtain an accurate diagnosis when studying focal liver lesions (FLL). It is
necessary to have an in-depth knowledge of the biologic and histologic characteristics of
FLL and the enhancement mechanism of LSCM to gain significant accuracy in the
differential diagnosis of FLL. It is possible to subdivide FLL into three main groups
according to the cinetic of contrast enhancement: hypervascular FLL, hypovascular FLL,
and FLL with delayed enhancement. Dynamic contrast-enhanced magnetic resonance
imaging is an important tool in the identification and characterization of FLL. LSCM
with a first phase of extracellular distribution give both dynamic (morphologic) and late
phase (functional) information useful for lesion characterization. With LSCM it is pos-
sible to differentiate with high accuracy benign from malignant lesions and hepatocel-
lular from nonhepatocellular lesions. To understand contrast behavior after injection of
LSCM, it is necessary to correlate contrast enhancement with the biologic and histologic
findings of FLL. Key Words: Liver—Neoplasms—Magnetic resonance—Contrast
media.
INTRODUCTION
Magnetic resonance imaging (MRI) is an established
imaging method for evaluation of focal liver lesions, al-
though the accuracy of unenhanced MRI for lesion char-
acterization is comparatively low (1,2). To adequately
characterize focal hepatic lesions on MRI, it is necessary
to use contrast media (CM) that are able to modify the
signal intensity of either the lesion or the normal liver
parenchyma and thus contribute to characterization of the
lesion (3–6).
The sensitivity of MR to the variations of signal inten-
sity induced by CM has led to the development of several
different types of CM, which use the paramagnetic prop-
erties of gadolinium (Gd) or manganese or the superpara-
magnetic properties of iron. The various CM can be dis-
tinguished on the basis of their distribution after
intravenous injection.
OVERVIEW OF CONTRAST AGENTS
Nonspecific Gd chelates such as Gd-DTPA (Magnevist,
Schering AG, Berlin, Germany) and Gd-DTPA-BMA
(Amersham Health, Oslo, Norway) (7) that distribute in
the extracellular fluid (ECF) space currently are the most
widely used CM. These CM are most effective during the
dynamic phase of contrast enhancement when differential
blood flow between tumor and normal liver parenchyma
leads to characteristic lesion enhancement patterns (4,5).
Unfortunately, dynamic phase imaging alone can, at
times, prove unsatisfactory for the accurate diagnosis of
hepatic lesions (1).
The development of CM with liver-specific properties
has increased the accuracy of MR for the identification
and characterization of focal liver lesions (8–11).
Exclusive distribution to the hepatocellular compart-
ment can be obtained using CM that–when injected by
slow infusion–accumulate within the hepatocytes and
cause an increase in the proton relaxation rate. In manga-
fodipir trisodium (Mn-DPDP, Teslascan, Nycomed, Oslo,
Norway), the manganese ion is chelated with four mol-
ecules of meglumine. The molecule is isotonic with the
blood and has a low viscosity. In Europe it is infused
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slowly (2 to 3 mL/min over 10 to 20 minutes) at a con-
centration of 10 mmol/mL and at a dose of 0.5 mL/kg. In
the United States, a faster injection (about 1 minute) is
used. The need for slow infusion of Mn-DPDP and the
ensuing lack of a dynamic imaging capability has led
some authors to propose the possibility of sequential ad-
ministration of Gd chelates and Mn-DPDP in a single visit
to obtain both dynamic and late imaging (12).
After administration, the Mn2+ ion contained in the
molecule is gradually released into the blood from the
DPDP chelate and is substituted by zinc. The latter has an
affinity for the chelant that is hundreds of times greater
than that of Mn2+. The free Mn2+ then is available for
uptake into parenchymal cells, particularly those of the
liver, pancreas, kidneys, and adrenals in which metabo-
lism of this metal takes place. The maximum tissue en-
hancement is observed at the end of the infusion after
approximately 20 minutes and lasts for about 4 hours (13).
The liver parenchyma enhances significantly after Mn-
DPDP administration. Tumors of nonhepatocytic origin
show little or no tumor enhancement, resulting in in-
creased lesion conspicuity. Several studies have shown
improved lesion detection on images obtained after infu-
sion of Mn-DPDP compared with precontrast images
(14,15). However, uptake of Mn2+ after Mn-DPDP infu-
sion has been observed in hepatic metastases from non-
functioning endocrine tumors of the pancreas (16).
Many hepatocellular lesions, on the other hand, show
mass enhancement, thereby resulting in decreased tumor
liver contrast/noise ratio (CNR). An investigation aimed at
evaluating Mn-DPDP for the study of hepatocellular car-
cinoma (HCC) demonstrated poor efficacy of this agent
for the identification of these lesions (17).
In a recent multicenter study, Mn-DPDP–enhanced
MRI in 77 patients with histologically confirmed lesions
had a sensitivity and specificity in differentiating lesions
of 91% and 67% (malignant versus benign lesions) and
91% and 85% (hepatocellular versus nonhepatocellular
lesions), respectively (18). Uptake of Mn-DPDP, and
therefore enhancement, by both benign and malignant he-
patic neoplasms limits the accurate differentiation be-
tween benign and malignant tumors of hepatocellular na-
ture (17–20) and represents a major shortcoming of this
agent.
Other CM demonstrate combined perfusion and hepa-
tocyte-selective properties. Such compounds distribute
initially to the vascular-interstitial compartment in a man-
ner analogous to that of conventional extracellular CM.
Thereafter, a fraction of the injected dose is taken up into
the hepatocytes, causing an increase of the signal intensity
of the hepatic tissue. Agents of this type include gadoben-
ate dimeglumine (Gd-BOPTA), which is approved in Eu-
rope for clinical use, and gadolinium-ethoxybenzyl-
diethylenetriaminepentaacetic acid (Gd-EOB-DTPA),
which is in an advanced phase of development.
Gadobenate dimeglumine (Gd-BOPTA, MultiHance,
Bracco Imaging S.p.A., Milan, Italy) is a chelate of the
paramagnetic Gd ion, salified with two molecules of meg-
lumine. Gd-BOPTA is a second-generation Gd chelate
that combines the properties of a conventional extracellu-
lar Gd agent with those of an agent targeted specifically to
the liver (21).
Two features that distinguish Gd-BOPTA from the con-
ventional Gd chelates are a capacity for weak and transient
interaction with serum albumin (22) and an elimination
profile in which approximately 96% of the injected dose is
excreted renally via glomerular filtration; the remaining
2% to 4% taken up by functioning hepatocytes is elimi-
nated in the bile via the hepatobiliary pathway (23).
Whereas the former feature confers on Gd-BOPTA a two-
fold greater T1 relaxation rate in vivo, the latter leads to a
marked and long-lasting enhancement of the signal inten-
sity of normal liver parenchyma, resulting in an additional
delayed imaging window beginning 40 minutes after Gd-
BOPTA administration (24).
Studies have shown that although Gd-BOPTA behaves
in a manner analogous to conventional Gd agents during
the dynamic phase of contrast enhancement (25), in the
delayed phase it not only improves the impact of MRI for
the detection of focal liver lesions (3,26) but it also may
contribute to the improved characterization of detected
lesions, particularly lesions demonstrating atypical en-
hancement on dynamic imaging (27,28).
Gadolinium ethoxybenzyl-diethylenetriaminepentaace-
tic acid (Gd-EOB-DTPA, Schering AG) exploits the “car-
rier” used by hepatocytes for the uptake of bilirubin (29).
In a manner analogous to that of Gd-BOPTA, this CM
distributes initially to the vascular-interstitial compartment
after injection. However, whereas only 2% to 4% of the
injected dose of Gd-BOPTA is taken up by hepatocytes
and eliminated in the bile, in the case of Gd-EOB-DTPA
approximately 50% of the injected dose is taken up and
eliminated via the hepatobiliary pathway after approxi-
mately 60 minutes. The maximum increase of liver paren-
chyma signal intensity is observed approximately 20 min-
utes after injection and lasts for approximately 2 hours
(30). During the perfusion phase, the dynamic enhance-
ment patterns seen after injection of Gd-EOB-DTPA are
similar to those seen with Gd-DTPA, whereas during the
hepatobiliary phase Gd-EOB-DTPA–enhanced images
have been shown to yield a statistically significant im-
provement in the detection rate of metastases, HCCs, and
hemangiomas compared with unenhanced and Gd-
DTPA–enhanced images (11).
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Use of the superparamagnetic effect of iron oxide par-
ticles is based on a distribution in the reticuloendothelial
system (RES). Superparamagnetic CM consist of iron ox-
ide particles, coated with a polysaccharide, whose para-
magnetic ions produce domains of spontaneous magneti-
zation that align their magnetic dipole moments with and
become strongly magnetized by an external magnetic field
(31,32). The presence of superparamagnetic iron oxide
(SPIO) locally augments the externally applied magnetic
field, producing magnetic field heterogeneity that, in turn,
promotes dephasing and results in signal loss from en-
hanced T2 relaxation. SPIO particles are cleared from the
blood by phagocytosis accomplished by RES, usually
lacking in most malignant liver lesions, so that uptake is
observed in the normal liver, spleen, bone marrow, and
lymph nodes (33). Inflammation, scarring, regeneration,
and shunting in cirrhotic liver reduces hepatic uptake of
SPIO, shifts distribution to the spleen, and produces signal
heterogeneity.
Cirrhotic liver tissue can show an inhomogeneous de-
crease of liver signal intensity, representing collagenous
structures. Nevertheless, Yamashita et al. (34) observed
that the uptake of SPIO did not correlate with chronic liver
parenchymal pathology, indicating that Kupffer cells ac-
tivity does not correlate with progress of periportal fibro-
sis, although reductions in signal intensity were small in
severely cirrhotic liver. This is probably because the func-
tional status of Kupffer cells is closely correlated with
hepatic function rather than the degree of fibrosis, sug-
gesting that a larger amount of SPIO might be required to
obtain sufficient contrast in patients with poor liver func-
tion.
Most focal liver lesions, mainly those that are malig-
nant, lack Kupffer cells or the capacity to take up particles.
After SPIO injection the darkening of normal liver paren-
chyma that surrounds focal liver lesions increases the
CNR of these lesions, usually slightly hyperintense on
precontrast T2-weighted images, which appear more hy-
perintense on T2-weighted images.
The T1 relaxivity of SPIO is a function of the surface
area, because it requires intimate contact between water
molecules and the surfaces of the iron oxides. It increases
when the particles are dispersed in the solvent and no
longer concentrated in a small volume. Therefore, a T1
effect predominates at low concentrations. SPIO particles
are taken up by Kupffer cells and concentrated in lyso-
somes in the form of a cluster. In this configuration the
small particles behave like large inhomogeneously distrib-
uted ferrite particles and distort the local magnetic field.
For this reason T2* is significantly shortened and obscures
any effect, even on T1-weighted images (35).
Several studies have attempted to determine the optimal
pulse sequence for post-SPIO imaging of hepatic lesions.
Pulse sequences that are sensitive to magnetic field het-
erogeneity tend to be sensitive to the presence of iron
oxide. T2*-weighted gradient-echo images are sensitive to
SPIO (36), whereas T2-weighted spin-echo images are
more sensitive than T2-weighted fast spin echo, as the
multiple rephasing pulses used in the latter tend to obscure
signal losses arising from local variations in the magnetic
environment (37). Echo-planar images are sensitive to
SPIO (38).
In a recent study, Alger et al. (39) found that CNR
differences attributable to TE variation over the range
from 46 to 106 milliseconds were less than 34% for a
0.2-T unit, and TE of 46 milliseconds yielded a statisti-
cally significantly greater CNR than did TE of 76 or 106
milliseconds. The same was true at the higher field
strength, but differences were not significant. The authors
also found that post-SPIO CNR was significantly greater
at 1.5 T than at 0.2 T. Moreover, in the specific case of
post-SPIO liver imaging there is no agreement in the
evaluation of string field influence. Deckers et al. (40)
found no significant CNR differences between 0.2 and 1.5
T, whereas Alger et al. (39) found the opposite.
A variety of iron oxides have been developed for CM-
enhanced MRI. Two different classes of iron oxides are
commercially available or in phase III clinical trials: su-
perparamagnetic ferumoxides (SPIO) and ultrasmall su-
perparamagnetic iron oxides (USPIO).
Ferumoxides (Feridex IV, Berlex Laboratories Wayne,
NY, USA; and Endorem, Guerbet, Aulnay Sous Bois,
France) was developed by Advanced Magnetics (Cam-
bridge, MA, USA) and is referred to as AMI-25. It has
been commercially available in Europe since 1995 and
was introduced to the U.S. market in 1996. Ferumoxides is
an SPIO colloid with low-molecular-weight dextran, with
a particle size of 50 to 180 nm according to the analytical
system used (electron microscopy or photo correlation
spectroscopy) (41).
About 8 minutes after intravenous injection, iron oxide
particles are taken up by the reticuloendothelial cells in the
liver (Kupffer cells) and in the spleen, with approximate
uptake of 80% and 6% to 10%, respectively (33). Maxi-
mum signal loss is obtained after 1 hour, with an imaging
window ranging from 30 minutes to 6 hours after injection
(42,43). Most studies in the United States and Japan used
a dose of 10 mmol/kg, whereas the recommended dose in
Europe has been 15 mmol/kg. To reduce the incidence of
side effects such as hypotension, ferumoxides is prepared
as a dilution in 100 mL of 5% dextrose and administered
as a drip infusion over 30 minutes. Hypotension and lum-
bar pain represent the most frequent symptoms associated
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with SPIO administration, with an incidence ranging from
2% to 10% (41).
Clinical efficacy of ferumoxides for detection focal
liver lesions on T2-weighted images has been investigated
in several trials, most of which supported the value of
postcontrast images for detection of solid liver lesions. In
a multicenter trial, ferumoxides-enhanced T2-weighted
images revealed additional lesions not seen on unen-
hanced images in 27% of cases and additional lesions not
seen by conventional (nonspiral) computed tomographic
(CT) scans in 40%. The additional information would
have changed therapy in 59% (43). A comparison with
spiral CT demonstrated a better sensitivity of SPIO-
enhanced MR images but at the expense of reduced speci-
ficity with a higher number of false-positive results (44).
Other studies comparing the efficacy of SPIO-enhanced
T2-weighted MRI with CTAP showed higher sensitivity
and specificity of MRI, especially with T2*-weighted
breath-hold gradient-recalled echo (GRE) images. Those
images were effective in distinguishing metastases from
small cysts, a source of false-positive results for CTAP
(45). A previous study demonstrated a better sensitivity of
CTAP when performed with spiral CT (46).
SHU 555 A (Ferucarbotran) is the code name of an
SPIO contrast agent registered as Resovist (Schering AG).
It has been commercially available in some European
countries since 2001. The active particles are carboxydex-
tran-coated superparamagnetic iron oxide, with a hydro-
dynamic diameter ranging from 45 to 60 nm. The different
particle sizes determine the velocity of their uptake by
cells of the RES, especially the Kupffer cells in the liver,
as well as the relaxivity-related effects. SHU 555 A ex-
hibits a low viscosity and is isotonic to blood plasma. It is
the first liver-specific contrast agent for MRI consisting of
SPIO particles that can be administered as a fast bolus.
SHU 555 A has a strong effect on the shortening of T1
and T2 relaxation times. R1 and R2 relaxivities in blood
(at 1.5 T and 37°C) are 7.2 ± 0.1 and 82.0 ± 6.2 L/(mmol
× sec), respectively. Because of the high R2 relaxivity it is
particularly suited to T2-weighted and T2*-weighted im-
aging. Furthermore, SHU 555 A enables T1-weighted im-
aging with one tenth the standard dose of extracellular
contrast agents (Gd-DTPA), ensuring a valuable although
less pronounced T1 effect. Fast bolus injection of SHU
555 A makes possible observation of the early perfusion
characteristics of the liver using T1-weighted or T2*-
weighted sequences.
There are some interesting perspectives with regard to
dynamic imaging with SPIO enhancement that can be ad-
dressed with SHU 555. With rapid imaging during injec-
tion of SHU 555 A, while the particles are still in the
circulation, signal enhancement from intrahepatic vessels
can be seen on T1-weighted images. The designation of
vessels during this phase can provide a reference for in-
terpretation on delayed T2-weighted images. This presents
an opportunity to circumvent a previously reported limi-
tation of SPIO agents, i.e., the differentiation of the bright
signal intensity of small liver lesions from the bright sig-
nal intensity of blood vessels viewed in cross section may
be a challenge on delayed SPIO-enhanced MR images
(47).
During the perfusion phase the T1 effects of SPIO can
be exploited to assist in the diagnosis of hemangiomas
(48), a property that also is relevant to SHU55A (49).
Accumulation phase imaging (RES phase) can be per-
formed as early as 10 minutes after injection using T1-
weighted, T2-weighted, and T2*-weighted sequences. T2-
weighted and T2*-weighted accumulation phase imaging
improves the visualization, delineation, and conspicuity of
lesions and hence improves detection (50). However, the
combined approach of nonenhanced and SPIO-enhanced
T2-weighted MRI together resulted in a significantly
higher sensitivity and significantly more accurate differ-
entiation of benign from malignant lesions compared with
results from spiral CT images, nonenhanced T2-weighted
MRI, or SPIO-enhanced T2-weighted images alone (51).
AMI-227 (Advanced Magnetics) belongs to the USPIO
class of iron oxide compounds. AMI-227 is known by
different code names during clinical trials. It consists of a
5-nm–diameter iron oxide core coated with low-
molecular-weight dextran, yielding a particle with a mean
diameter of 17 to 20 nm. The smaller particle size results
in a long intravascular half-life of more than 200 minutes;
thus, AMI-227 is considered a blood pool agent (52). The
uptake of AMI-227 in the RES system is more delayed
compared with SPIO, and there is greater bone marrow
and lymph node uptake than occurs with larger SPIO (41).
As is typical of iron oxide contrast agents, AMI-227
shows preferential or selective accumulation in the liver
parenchyma, resulting in signal loss in the liver on T2-
weighted images. Most solid liver tumors, particularly me-
tastases, which lack phagocytic activity, do not show sig-
nificant signal intensity decrease, resulting in augmented
CNR between liver and metastases.
On T1-weighted images there is signal enhancement in
the distribution site of the USPIO, including liver tissue,
blood, and hemangiomas. After AMI-227 administration
hemangiomas are bright on T1-weighted images and lose
signal on T2-weighted images. This is different from me-
tastases, which remained unchanged on T1-weighted and
T2-weighted postcontrast images (53). In that study, about
87% of all hemangiomas demonstrated uniform hyperin-
tensity on T1-weighted postcontrast images. Conversely,
HCC and hypervascular metastases lacked uniform hyper-
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intensity on T1-weighted images after administration of
USPIO. This difference in T1 enhancement characteris-
tics, in association with the characteristic drop in signal
intensity for hemangiomas on T2-weighted postcontrast
images, facilitated high sensitivity and specificity values
in the characterization of these lesions.
Demonstration of ring enhancement after USPIO has
been proposed as a means to differentiate benign from
malignant liver lesions. With USPIO, it has been sug-
gested that this rim enhancement may be due to blood pool
enhancement in peripheral vessels surrounding malignant
tissue (54). In one report, hemangioma rarely demon-
strated ring enhancement, whereas metastases showed
ring enhancement in about 30% of the cases, providing a
helpful sign to differentiate hemangiomas from malignant
liver lesions (53).
BEHAVIOR OF FOCAL LESIONS IN RESPONSE
TO CONTRAST MEDIA
A practical approach to focal hepatic lesions involves
classifying the behavior of lesions on dynamic imaging
with contrast media that distributes in the ECF spaces,
so-called ECF agents. This is the most frequently used
method for characterization of focal hepatic lesions relied
upon for both MRI and CT. This approach yields methods
to facilitate the detection and characterization of lesions,
the latter relying upon recognition of distinctive patterns
of enhancement.
The hypervascular liver lesions consist of a wide range
of lesion types, ranging from physiopathologic to patho-
logic. Among these lesion types are benign and malignant
lesions of both hepatocellular and nonhepatocellular origin.
The discussion of hypervascular lesions begins with
benign focal masses derived from hepatocellular origins.
Benign focal masses derived from
hepatocellular origins
Focal nodular hyperplasia (FNH) is the second most
common benign lesion of the liver behind hemangioma. It
is present in 3% to 5% of the population and is more
common in women of child-bearing age (55). The cellular
structure of FNH is similar to that of normal hepatic pa-
renchyma apart from the presence of an abnormal biliary
system. FNH is a benign tumor-like lesion that results
from a hyperplastic rather than a neoplastic process (56).
In more than one third of cases the lesion develops
asymptomatically and is discovered incidentally. In other
cases there may be some signs or symptoms indicative of
its presence. In roughly 85% of cases only a single nodule
of FNH is present. The margins of the lesion usually are
well defined, and its size is generally smaller than 5 cm,
although lesions between 8 and 10 cm can be encountered
(57). Given the low risk of rupture and hemorrhage and
the low level of malignancy, FNH frequently is left un-
treated but with regular follow-up examinations, particu-
larly of asymptomatic cases (58).
On T1-weighted MRI, FNH appears isointense or
slightly hypointense to the surrounding liver parenchyma
and may show a central hypointense scar. On T2-weighted
images the lesion is slightly hyperintense. Contrast-
enhanced dynamic phase MRI using traditional ECF Gd-
based contrast agents gives similar dynamic information
as CT and provides the greatest diagnostic sensitivity
among the techniques in current use. This is the case when
dynamic MR data are combined with the information
available on unenhanced T1-weighted and T2-weighted
images (59).
Dynamic MRI shows a marked enhancement in the
arterial phase of the lesion, which persists as slightly hy-
perintense or isointense in the portal venous and distribu-
tion phase (Figs. 1 and 2), whereas the central scar appears
hypointense in the arterial and portal venous phase to be-
come hyperintense in the distribution phase (Fig. 2e).
Accurate characterization of FNH is not always pos-
sible because atypical features can confound the interpre-
tation. In a recent study the majority (86%) of small (3 cm
or less) FNH did not have a visible scar on unenhanced or
enhanced dynamic phase scans (28). Other investigators
reported similar findings on MR and CT (60–62). Al-
though the absence of a scar in small FNH cannot be
considered “atypical,” it makes it more difficult to distin-
guish FNH from other hypervascular neoplasms.
MR contrast agents with liver-specific properties are
helpful in characterizing FNH. In FNH, there is prolonged
and excessive hepatocellular accumulation of hepatocytic-
specific CM due to the structural alteration of the biliary-
canalicular system that does not communicate with or de-
rive from the surrounding normal hepatic biliary system
(63).
Gd-BOPTA offers the possibility of dynamic imaging
and evaluation of delayed phase images. The Gd-BOPTA
enhancement dynamics of FNH in the early phases paral-
lel those seen with ECF agents. On T1-weigted images
substantial enhancement is noted within the parenchyma
of the lesion, whereas the central scar, which is the prin-
cipal site of the biliary metaplasia, appears consistently
hypointense in the delayed phase. The lesion appears
isointense or hyperintense to the surrounding liver, with
three different patterns of enhancement frequently ob-
served: homogeneous (Fig. 1e), peripheral (Fig. 2f), or
heterogeneous (Fig. 3e) (28). Similar findings have been
observed with Mn-DPDP (Fig. 1f) (19).
Kupffer cells usually are observed within FNH and,
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along with malformed bilary ducts, are a major histologic
feature of this lesion. Uptake of SPIO by FNH is common,
with the lesions showing significant decreases in signal
intensity on ferumoxides-enhanced T2-weighted images
(64). Signal drop reflects the presence of Kupffer cells
within the lesion.
Nevertheless the amount and distribution of Kupffer
cells within the nodule can vary and yield different pat-
terns of signal decrease: some small FNH (less than 3 cm)
show homogeneous signal drop similar to that observed in
the surrounding parenchyma, whereas large FNH may
show heterogeneous signal drop (Fig. 3g). The central scar
excludes iron particles and is readily demonstrated as hy-
perintense central stellate area. That finding corresponds
to the high signal area seen on T2-weighted precontrast
images but higher conspicuity generally is found after the
use SPIO agents (Fig. 2g) (65).
In a comparison of 33 patients with 55 FNH studied
with Gd-BOPTA and with SPIO (Endorem), 16 (29%) of
55 smaller lesions were not visible on T2-weighted images
both before and after SPIO, whereas all lesions were vis-
ible on dynamic phase imaging with Gd-BOPTA. Overall,
typical behavior was observed for 52 (94.5%) of 55 le-
sions after Gd-BOPTA and for 24 (61.5%) of 39 visible
lesions after Endorem. MRI with Gd-BOPTA was supe-
rior to MRI with Endorem for the identification and char-
acterization of FNH (100% versus 71% and 94.5% versus
61.5%, respectively) (66).
Nodular regenerative hyperplasia (NRH) of the liver is
not a specific entity but is a secondary and nonspecific
tissue adaptation to heterogeneous distribution of blood
flow, characterized by multiple monoacinar regenerative
nodules in the absence of fibrous septa. These lesions can
be imaged when the nodules become confluent. NRH oc-
curs in 5.6% of individuals older than 80 years and with
increased frequency in patients with systemic arthritis,
polymyalgia rheumatica, massive tumor infiltration, and
mineral oil deposition (67). Clinically NRH presents pri-
marily with manifestations of noncirrhotic portal hyper-
tension in about 50% of the patients. Management is di-
rected primarily to portal hypertension and variceal
bleeding, which is the main source of mortality. Liver
failure is uncommon because of satisfactory preservation
of liver function (68). Malignant transformation of the
nodules has never been reported.
On unenhanced MRI, NRH is isointense to hypointense
on T2-weighted images and hyperintense to isointense on
T2-weighted images. On contrast-enhanced dynamic
phase MRI with extracellularly distributed CM, the lesion
appears hyperintense during the arterial phase and isoin-
FIG. 1. Atypical focal nodular hyperplasia in 34-year-old woman with chronic right upper abdominal pain. a: SE transverse T2-weighted image shows
a large homogeneous slightly hyperintense lesion in the right lobe of the liver, without any evidence of central scar. b: GRE transverse T1 precontrast
image. The lesion is homogeneously isointense to the surrounding liver parenchyma. During dynamic imaging (GRE transverse T1-weighted), the lesion
is homogeneously hyperintense at arterial phase. c: At 25 seconds after bolus administration of Gd-BOPTA, large peripheral feeding vessels are evident
(arrows). d: In the portal venous phase obtained 90 seconds after the injection, the lesion persists as slightly hyperintense, but there is no evidence of
scar. e: GRE transverse T1-weighted images obtained 2 hours after administration of Gd-BOPTA. There is homogeneous enhancement of the liver, and
the lesion appears homogeneously isointense. The main biliary duct is hyperintense due to biliary elimination of Gd-BOPTA (arrow). f: Follow-up after
1 year. GRE transverse T1-weighted images obtained 1 hour after administration of Mn-DPDP. There is homogeneous enhancement of the liver, and the
lesion appears markedly hyperintense. No scar is appreciable. With this contrast media the main biliary duct is hyperintense because of biliary elimination.
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tense or slightly hyperintense in the portal and equilibrium
phases (Fig. 4e and f) (69,70). Both with Gd-BOPTA and
Mn-DPDP the lesion appear isointense or hyperintense to
the surrounding liver parenchyma in the hepatobiliary
phase (Fig. 4g and h). The appearance of NRH with SPIO
CM has not yet been described, but because of the histo-
logic characteristics of NRH its behavior is expected to be
similar to that observed for FNH.
Hepatic adenoma (HA) is a benign neoplasm that typi-
cally is found in women with a history of oral contracep-
tive use (71,72). It is also seen in patients with type I
glycogen storage disease (73). In these subjects, the HAs
are likely to be multiple and more often undergo malig-
nant transformation, although the latter still is considered
rare (74). Other predisposing conditions, such as iron
overload, have been described (75).
HA consist of plates or cords of cells that are larger than
normal hepatocytes and contain large amounts of glyco-
gen and lipid. Lipid accumulation is responsible for the
characteristic yellow appearance of the cut surface of ad-
enomas at pathology, and evidence of lipid at CT or MRI
can be suggestive in diagnosing hepatocellular adenoma.
The plates are separated by dilated sinusoids, which are
thin-walled capillaries perfused by arterial pressure, but a
portal venous supply is lacking. A tumor capsule usually
is absent or incomplete. Kupffer cells often are found in
HA but in reduced numbers and with little or no function,
as reflected by the absent or diminished uptake of tech-
netium (Tc)-99m sulfur colloid (76). Even though HA
have functioning hepatocytes, they lack bile ducts, a key
histologic feature that helps distinguish HA from FNH
(63). It is likely that bilirubin metabolism is blocked
FIG. 2. Focal nodular hyperplasia in a 31-year-old woman. a: SE transverse T2-weighted image
shows a homogeneous slightly hyperintense lesion in the right lobe of the liver. Central stellate scar
is hyperintense. b: GRE transverse T1 precontrast image. The lesion is homogeneously isointense
to the surrounding liver parenchyma. The central scar (curved arrow) is hypointense. c: During
dynamic imaging the lesion is hyperintense and homogeneous at arterial phase obtained 25 seconds
after bolus administration of Gd-BOPTA. The central scar is hypointense. d: In the portal venous
phase obtained 90 seconds after the injection, the lesion persists slightly hyperintense. The scar
remains hypointense. e: At equilibrium phase obtained 5 minutes after administration of Gd-
BOPTA, the lesion is slightly hyperintense to adjacent liver parenchyma. The central scar is
hyperintense. f: GRE transverse T1-weighted images obtained 3 hours after administration of
Gd-BOPTA. There is homogeneous enhancement of the liver, and the nodule appears peripherally
hyperintense. The scar is hypointense. g: SE transverse T2-weighted image 1 hour after Endorem
administration. Homogeneous signal drop is observed throughout the liver and the lesion, which
persists as slightly hyperintense to the surrounding liver parenchyma. The central scar excludes iron
particles uptake and appears with higher conspicuity.
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within the HA, as confirmed by the absence of bile within
resected HAs (77).
Most patients are asymptomatic with normal liver func-
tion. Large HA may cause a sensation of right upper quad-
rant fullness or discomfort. The classic clinical manifes-
tation of HA is spontaneous rupture or hemorrhage,
especially for large and multiple adenomas, leading to
acute abdominal pain and possibly progressing to hypo-
tension or even death (77). Thus, there is a clinical indi-
cation for the surgical removal of large (greater than 5 cm)
HA.
At MRI, HAs have a wide variety of appearances and
have been variously described as hyperintense, isointense,
and hypointense lesions (5,78,79). Areas of increased sig-
nal intensity on T1-weighted MRI can result from fat
(35%–77%) and hemorrhage (52%–93%) (80–82),
whereas low signal intensity areas correspond to necrosis,
old hemorrhage, or calcifications (80). Some 47% to 74%
FIG. 3. Atypical focal nodular hyperplasia and
cavernous hemangioma in a 65-year-old
woman. a: SE transverse T2-weighted image
shows a large markedly hyperintense lesion
with a central area of low signal in the right lobe
of the liver. A smaller slightly hyperintense area
without scar can be seen medial to this lesion.
Other hyperintense lesions can be seen in the
left lobe (cysts). b: GRE transverse T1 precon-
trast image. The larger lesion is markedly hy-
pointense, whereas the smaller lesion is slightly
hypointense to the surrounding liver paren-
chyma. During dynamic imaging with bolus ad-
ministration of Gd-BOPTA (GRE transverse
T1-weighted), the larger lesion shows a globu-
lar peripheral enhancement, whereas the smaller
lesion is homogeneously hyperintense at arterial phase (25 seconds after bolus administration) (c), to become slightly hyperintense in the portal venous
phase (90 seconds after the injection) (d), and isointense at the distribution phase (3 minutes after the injection) (e). There is no evidence of scar. f: GRE
transverse T1-weighted images obtained 1 hour after administration of Gd-BOPTA. There is homogeneous enhancement of the liver, and the larger lesion
appears hypointense with the central fibrotic area slightly hyperintense due to pooling of CM. The smaller lesion appears inhomogeneously isointense.
(g,h) Follow-up at 18 months, 1 hour after administration of Endorem. g: SE transverse T2-weighted images. Homogeneous signal drop is observed
throughout the liver and the larger lesion, which persists slightly hyperintense to the surrounding liver parenchyma. The smaller lesion shows inhomo-
geneous uptake of SPIO; thus, it appears slightly more hyperintense than in the unenhanced study. h: GRE transverse T1-weighted image. The
hemangioma appears hyperintense with the exception of the central fibrotic area. The focal nodular hyperplasia is isointense.
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of HAs are predominantly hyperintense on T2-weighted
images; the remainder are isointense or hypointense. Most
lesions are heterogeneous, demonstrating a combination
of hyperintensity and hypointensity on T2-weighted im-
ages relative to hemorrhage and necrosis (Fig. 5a). One
third of HAs have a peripheral rim corresponding to a
fibrous capsule (81).
Dynamic Gd-enhanced MRI, whether performed with
ECF agents or liver targeted agents, can demonstrate early
arterial enhancement (although this usually is less marked
than in cases of FNH) that becomes isointense or hypoin-
tense in the portal venous phase (Fig. 6a–d). In case of
previous hemorrhage, the arterial enhancement can be in-
homogeneous (Fig. 5b–e).
On delayed phase images after injection of Gd-BOPTA
there is little evidence of uptake by HAs, which appear
FIG. 4. Nodular regenerative hyperplasia in a 65-year-old man with a large peripheral cholangiocarcinoma. a: Nonenhanced T2-weighted SE transverse
image shows a large hyperintense mass in the right lobe. b: At another level the T2-weighted SE sequence shows no lesions. c: On precontrast
T1-weighted GRE image at the same level shown in panel a, the mass is hypointense compared with the parenchyma. d: PrecontrastT1-weighted images
showed no lesions at the same level shown in panel b. Images obtained at the levels shown in panels b and d during dynamic imaging with Gd-BOPTA
(GRE transverse T1-weighted) show multiple hypervascular lesions in the arterial phase (e), which appear isointense in the portal venous phase (f).
Images obtained in the hepatobiliary phase, 1 hour after Gd-BOPTA injection, show that the large lesion is hypointense centrally on T1-weighted GRE
coronal image with some peripheral enhancement (g), whereas other lesions appear isointense or hyperintense. h: On T1-weighted GRE transverse image
1 hour after Mn-DPDP, the same behavior is observed, with the lesions from the levels shown in panels b and d being isointense or hyperintense. i: In
the surgical specimen the large cholangiocarcinoma shows a radiate aspect with a central fibrotic area, whereas the multiple nodules of nodular
regenerative hyperplasia appear more similar to normal liver.
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hypointense (Figs. 5f and 6e–f) (28). On the other hand,
the hepatocellular-specific contrast agent Mn-DPDP is
able to enter the abnormal hepatocytes, producing an
isointense or hyperintense appearance on delayed phase
images (Figs. 5g and 6g) (20).
HAs usually do not show uptake of SPIO particles,
resulting in increased tumor-liver CNR on T2-weighted
images (Fig. 6i). However, occasionally HAs have shown
some degree of uptake (64), with a heterogeneous signal
drop whose entity usually is lesser than in FNH (Fig. 5h).
Uptake of SPIO in HA appears to be due to pooling of the
contrast agent within the peliosis-like dilated vessels that
characterize them (83). However, in several cases, no sig-
nificant difference of signal loss was observed between
FNH and HA (65).
In 1985 liver adenomatosis was described as a separate
clinical entity, distinguished from isolated HA by the pres-
ence of multiple adenomas (arbitrarily, more than 10),
lack of correlation with steroid medication, occurrence in
both men and women, and abnormal increases in serum
alkaline phosphatase and gamma-glutamyltransferase lev-
els, in an otherwise normal liver and in patients without
glycogen storage disease (84–87). Association with vas-
cular anomalies have been described, such as portal ve-
FIG. 5. Hepatic adenoma in a 45-year-old
man. a: TSE T2-weighted transverse MRI
shows a large inhomogeneous isointense mass
pedunculated off the right lobe with focal areas
of hyperintensity. b: On unenhanced GRE T1-
weighted transverse image the lesion is isoin-
tense with areas of hypointensity corresponding
to the hyperintense areas on T2-weighted im-
ages. During dynamic imaging with Gd-
BOPTA (GRE transverse T1-weighted), the le-
sion shows inhomogeneous enhancement at the
arterial phase (c) and become hypointense in the
portal venous (d) and distribution phase (e),
where a peripheral hyperintense capsule is evi-
dent. f: GRE transverse T1-weighted image at
the hepatobiliary phase, 2 hours after Gd-BOPTA injection. The lesion appears slightly hypointense with areas of hyperintensity due to pooling of CM.
g: GRE transverse T1-weighted 1 hour after Mn-DPDP injection. The lesion appears isointense with a spot of hyperintensity in one component of the
lesion (arrowhead), corresponding to the hypervascular zone seen during the arterial phase (c). h: TSE T2-weighted transverse MRI 1 hour after injection
of Endorem. Inhomogeneous signal drop of the lesion (compare with panel a) showing some areas of hyperintensity.
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nous thrombosis, congenital absence of the portal vein,
and portosystemic venous shunt (88).
Histologically, the lesions consist of sheets of hepato-
cytes with foamy cytoplasm and uniform round nuclei.
Portal tracts and bile ducts are absent, but Kupffer cells
and fatty components can be present in some of the nod-
ules. Many of the nodules show evidence of subacute or
chronic hemorrhage. According to Chiche et al. (89), two
different forms of liver adenomatosis can be distin-
guished: massive and multifocal. Of these two types, the
FIG. 6. Hepatic adenomas in a 31-year-old woman previously operated upon for hemorrhagic hepatic
adenoma. a: At precontrast T1-weighted GRE transverse images there were no definite focal lesions. b:
During dynamic imaging with bolus administration of Gd-BOPTA (GRE transverse T1-weighted), a
hypervascular lesion can be seen at the right lobe, slightly hyperintense during the arterial phase. c: The
lesion appears hypointense in the portal venous phase and at the distribution phase (d). At the hepatobiliary
phase, 1 hour after Gd-BOPTA injection (e), homogeneous enhancement of the liver can be seen. The lesion
appears markedly hypointense. Note the biliary enhancement (arrow) as a consequence of the contrast
elimination (arrow). f: An image located more cranially also obtained 1 hour after Gd-BOPTA shows an
another smaller lesion (arrow). g: In the delayed hepatobiliary phase after Mn-DPDP administration (GRE
transverse T1-weighted), the lesion appears slightly hyperintense to background liver. h,i: SE transverse
PD-weighted image before (h) and 1 hour after (i) the administration of Endorem. h: No lesion can be seen. i: Homogeneous signal drop is observed
throughout the liver. The lesion shows a lack of SPIO uptake; thus, it appears hyperintense to the surrounding liver parenchyma. j: Surgical specimen.
The large lesion and the small lesion (arrow) seen on MRI can be appreciated. Another smaller lesion can be seen at pathology (arrowhead).
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former has an increased risk of malignant degeneration
and hemorrhage. The natural history and pathogenesis of
liver adenomatosis are unclear. Because of the chance of
malignant degeneration and hemorrhage, resection of ad-
enomas is warranted in many cases, even if some smaller
adenomas remain in place (84,85). Orthotopic liver trans-
plantation may be reserved for patients who have progres-
sive signs or symptoms after partial resection or in those in
whom HCC is suspected (88).
MRI shows variable lesion heterogeneity and signal in-
tensity. In general the images appear similar to hepatic
adenomas as previously described. On T2-weighted im-
ages, most of the adenomas are heterogeneously moder-
ately hyperintense or homogeneously isointense (Fig. 7a).
Noncomplicated lesions are generally isointense to the
liver parenchyma on T1-weighted images (Fig. 7b). Intra-
tumoral fat is heterogeneously hyperintense on T1-
weighted images, whereas intratumoral hemorrhage, when
present, appears heterogeneously hyperintense on T1-
weighted and T2-weighted images. In opposed-phase
chemical shift imaging, lesions show signal dropout,
which is indicative of lipid content.
On Gd-enhanced MRI most adenomas are hyperintense
on arterial and early portal venous phase images, whereas
on late portal venous phase images and equilibrium phase
images most appear isointense or homogeneously hypoin-
tense (Fig. 7c–e). On delayed phase images after injection
of Gd-BOPTA most lesions appear hypointense, indicat-
ing a lack of uptake by the lesions (Fig. 7f). On the other
hand, Mn-DPDP is able to enter the abnormal hepato-
cytes, resulting in a hyperintense appearance on delayed
phase images (Fig. 7g). After intravenous administration
FIG. 7. Liver adenomatosis in a 25-year-old woman with juvenile pylethrombosis at age 6
months. a: On TSE HASTE transverse MRI a large isointense lesion with a central hyperintense
area (arrow) can be seen in the right lobe. The borders of the lesion are difficult to identify. b: On
precontrast T1-weighted GRE transversal images the lesion is isointense, with a hypointense
central area. During dynamic imaging with bolus administration of Gd-BOPTA (GRE transverse
T1-weighted), multiple hypervascular lesions can be appreciated during the arterial phase (c),with
the larger lesion at the center of the right lobe. During the portal venous (d) and distribution phases
(e), the lesions become isointense or hypointense). In the hepatobiliary phase (GRE transverse
T1-weighted), 3 hours after Gd-BOPTA injection (f), all lesions are hypointense. g: GRE trans-
verse T1-weighted image 1 hour after Mn-DPDP injection. The large central lesion is isointense
to the surrounding parenchyma, and no other lesions can be seen.
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of ferumoxides particles, adenomas show variable uptake
of the contrast material, with lesion conspicuity decreasing
at intermediate-weighted and T2-weighted imaging.
Malignant focal liver lesions: Hepatocyte origin
HCC is the most frequent primary tumor of the liver
(80%–90%) and represents more than 5% of all cancers,
with an incidence of more than 500,000 new cases per
year throughout the world (90). Its incidence in develop-
ing countries is two to three times higher than in devel-
oped countries, although its incidence is rising in western
countries and in Japan (91). The most significant risk fac-
tor, regardless of etiology, is the presence of liver cirrhosis
(92), particularly when secondary to viral infection and
high alcohol intake. Other risk factors include hemochro-
matosis and primary biliary cirrhosis (90).
HCC is the endpoint of a serial transformation begin-
ning from a dysplastic nodule. HCC can develop from a
dysplastic nodule in as few as 4 months (93–95). Accord-
ing to the terminology of an international working party in
1994, there are three steps in the development of HCC:
regenerative nodule, dysplastic nodule (low grade; high
grade; with focus of HCC), and small HCC (less than 2
cm) (96).
Regenerative nodules are benign lesions with exclusive
portal venous blood supply and represent a nonspecific
response to a variety of insults to the liver. Low-grade
dysplastic nodules show slight cytologic atypia, mainly
large cell changes, whereas high-grade dysplastic nodules
are premalignant lesions that can demonstrate enhance-
ment during the arterial phase on MRI and CT. These
lesions can be diagnosed incorrectly as HCC when arterial
phase enhancement is seen, although this is a rare circum-
stance for dysplastic nodules (97,98).
Considered premalignant lesions, dysplastic nodules
pose a higher risk for development of HCC in patients
with than those without dysplastic nodules. In about one
third of high-grade dysplastic nodules small foci of carci-
nomas can be found; thus these nodules are termed “dys-
plastic nodules with focus of HCC.”
Dysplastic nodules have been described as demonstrat-
ing hyperintensity on T1-weighted images and hypointen-
sity on T2-weighted images (99,100). Although arterial
phase enhancement as a criterion for dysplastic nodule can
increase the sensitivity for characterization, this is at the
expense of decreased specificity because of the overlap
with the much more commonly seen arterial phase en-
hancement in HCC (97). When HCC elements are found
in a lesion smaller than 2 cm, they are called “small
HCC.” These lesions demonstrate arterial phase enhance-
ment more frequently than dysplastic nodules on all im-
aging modalities.
The macroscopic appearance of HCC has been classi-
fied as expanding, spreading, and multifocal. According to
Edmondson and Steiner (101), HCCs can be classified
from grades I to IV based on histologic differentiation. A
frequent observation, particularly in small HCC, is fatty
degeneration.
The formation of a pseudocapsule around the lesion
(constructed usually from connective fibrous tissue) and
of a septum within the tumor is frequently observed with
the development of HCC. This may derive from an inter-
action between tumor and host liver and may interfere
with the growth and invasion of the HCC (102).
Kupffer cells are present in HCCs. Although there are
no statistically significant differences in the numbers of
Kupffer cells between small well-differentiated HCCs and
noncancerous tissues, the numbers tend to decrease in can-
cerous tissues compared with noncancerous tissues as tu-
mor size increases and histologic grade decreases (103).
Many factors affect the visualization of primary focal
hepatic lesions during unenhanced and/or contrast-
enhanced MRI of the liver, e.g., the dimensions, compo-
sition and degree of vascularization of the lesion, the func-
tionality of the normal hepatic parenchyma, and the
residual hepatic functionality of the neoplastic cells them-
selves. Unfortunately such factors tend to vary from pa-
tient to patient, often making the behavior of a given HCC
lesion difficult to predict. Previous studies aimed at cor-
relating the appearance of HCC on MRI with the patho-
logic characteristics of the lesion reflect the difficulty in
drawing firm conclusions on the behavior of such lesions
(99,104–107).
HCCs are mildly to moderately hyperintense at turbo
T2-weighted and/or STIR imaging (Figs. 8a and 9a). On
T1-weighted images increased signal intensity (Fig. 9b)
correlates with a more well-differentiated histologic grade
than does isointensity or hypointensity (97,108). Hyper-
intensity on T1-weighted images is related to several fac-
tors, such as fatty metamorphosis, glycogen, clear cells,
and copper (109).
Dynamic T1-weighted imaging during the arterial
phase is of utmost importance for the detection of small
HCCs, because they may be occult at other pulse se-
quences and on portal venous and equilibrium phase im-
ages (97). Typically HCCs demonstrate arterial enhance-
ment at dynamic imaging (Figs. 8 and 9).
Yamashita et al. (106) demonstrated a correlation be-
tween tumor grade and peak contrast enhancement on
dynamic Gd-DTPA–enhanced gradient-echo FLASH im-
ages with a lower peak enhancement for smaller and well-
differentiated lesions. They also reported a statistical cor-
relation between peak contrast enhancement of the lesion
and an increased dilation of sinusoid-like spaces in
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moderately/poorly differentiated HCC as opposed to well-
differentiated HCC. This suggests a higher accumulation
of contrast agent in the sinusoid-like spaces of
moderately/poorly differentiated HCCs compared with
well-differentiated HCCs in the arterial phase of contrast
enhancement. However, these findings should be inter-
preted with caution because controversies regarding the
optimal timing to capture the arterial phase exist (110–
112) and may influence attempts to reproduce the results.
The pseudocapsule of HCC appears hypointense on un-
enhanced T1-weighted and T2-weighted spin-echo and
gradient-echo MRI sequences. On contrast-enhanced MRI
the enhancement is more evident on arterial phase images
but may persist into the equilibrium phase (Fig. 9e) (113).
Lesion enhancement is observed after injection of para-
magnetic contrast agents with liver-specific properties. In
an anecdotal case of high-grade dysplastic nodule exam-
ined with Gd-BOPTA, the lesion was hyperintense to the
surrounding liver parenchyma at the hepatobiliary phase
(Fig. 10).
Dynamic imaging of HCC with Gd-BOPTA is similar
to that observed with conventional vascular-interstitial
CM (Figs. 8 and 9). Delayed phase imaging (about 1 hour
after injection) reveals a number of different enhancement
patterns, with isointense, hypointense, and hyperintense
patterns possible (Figs. 8e, 9f, and 11e).
In a previous study we revealed a tendency for moder-
ately differentiated lesions to enhance to a greater extent
on delayed images compared with both well-differentiated
lesions and poorly differentiated lesions, although statis-
tical significance was not demonstrated for any of these
differences (114). In a retrospective analysis of 94 HCCs
with Gd-BOPTA, 89.4% were hypointense in the delayed
phase, whereas only 3.2% and 7.4% were hyperintense
and isointense, respectively (115). Manfredi et al. (27)
demonstrated that well-differentiated and moderately dif-
FIG. 8. Hepatocellular carcinoma in a 65-year-old man
with alcoholic cirrhosis. a: TSE T2-weighted transverse
MRI shows a small nodule slightly hyperintense in the
right lobe (arrow). b: On precontrast T1-weighted GRE
transversal images the lesion is not recognizable. During
dynamic imaging with bolus administration of Gd-
BOPTA (GRE transverse T1-weighted), the lesion is
markedly hyperintense in the arterial phase (c) and be-
comes isointense in the portal venous phase (d). In the
hepatobiliary phase (GRE transverse T1-weighted) 2
hours after Gd-BOPTA injection (e), the lesion is hypo-
intense with respect to the liver (arrow). The gallbladder
(*) is hyperintense because of the presence of contrast
media in the bile.
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ferentiated HCC show superior signal enhancement ratios
than poorly differentiated HCC on images acquired on a
0.5-T machine at 60 to 120 minutes after Gd-BOPTA
administration. This finding reflects the retention of suf-
ficient hepatocytic activity by these lesions to take up
Gd-BOPTA. A significant correlation was observed be-
tween the presence of intralesional bile and the degree of
enhancement of the lesions after Gd-BOPTA administra-
tion (114).
With the hepatobiliary agent Mn-DPDP, all hepatocel-
lular tumors demonstrate enhancement, with HCCs fre-
quently showing inhomogeneous enhancement (Fig. 12)
(19). Well-differentiated HCC enhance to a greater extent
than poorly differentiated HCC (17). A rim-like enhance-
ment on Mn-DPDP–enhanced MRI can be seen in HCC,
whose underlying mechanism has been attributed to sev-
eral causes. Peritumoral malignant infiltration into neigh-
boring normal liver parenchyma can result in intermin-
gling of nonhepatocellular malignant cells with normal
functioning hepatocytes in the peripheral region of liver
metastasis.
However, such a finding also has been in cholangiocar-
cinoma (116) and metastases (18), resulting from com-
pression of surrounding normal liver tissue by a metastatic
tumor mass. This compression may have led to impaired
Mn-DPDP excretion or persistent Mn-DPDP retention be-
cause of compressed bile canaliculi in these areas (117).
This finding leads to difficulties in differentiating metas-
tases from poorly differentiated HCC.
MRI after Mn-DPDP administration has been shown to
result in more accurate differentiation between benign
(FNH) and malignant (HCC) hepatocellular tumors than
unenhanced MRI, although absolute values for sensitivity,
specificity, and accuracy were not particularly satisfactory
(64.5%, 66.7%, and 65.1%, respectively) (118). A study
aimed at determining the efficacy of Mn-DPDP for the
evaluation of HCC revealed low overall efficacy for Mn-
DPDP–enhanced MRI compared with unenhanced MRI
FIG. 9. Hepatocellular carcinoma in a 53-year-old man with alcoholic cirrhosis. a: TSE T2-weighted transverse MRI shows a small nodule slightly
hyperintense in the right lobe (arrow). b: On precontrast T1-weighted GRE transversal images the lesion is hyperintense. During dynamic imaging with
bolus administration of Gd-BOPTA (GRE transverse T1-weighted), the lesion is hyperintense in the arterial phase (c) to become hypointense in the portal
venous (d) and distribution phase (e). In this phase a peripheral capsule is well evident (arrow). f: In the hepatobiliary phase (GRE transverse
T1-weighted) 2 hours after Gd-BOPTA injection the lesion is isointense.
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for the identification of lesions (49 lesions in 20 patients
for Mn-DPDP–enhanced MRI compared with 50 lesions
in 17 patients for unenhanced MRI) (17).
With SPIO particles, HCCs generally do not show a
significant decrease in signal intensity, although signal
intensity loss was seen in some individual HCCs (64). The
signal intensity of the normal liver does decrease, how-
ever, thereby improving the CNR of malignant focal liver
lesions (Fig. 13).
According to Lim et al. (119), HCC conspicuity after
SPIO depends on differences in the number of Kupffer
cells between the lesion and the surrounding cirrhotic
liver. Moderately or poorly differentiated HCCs show
large differences in the number of Kupffer cells compared
with the surrounding cirrhotic liver and thus demonstrate
a high CNR at SPIO-enhanced MRI. Dysplastic nodules
and most well-differentiated HCCs, on the other hand,
contain nearly the same number of Kupffer cells as the
surrounding cirrhotic hepatic parenchyma and therefore
are not well depicted on T2-weighted MR images (119).
Tang et al. (120) found significantly more lesions on Gd-
enhanced MRI compared with ferumoxides-enhanced
MRI in 53 patients (97/103 versus 80/103, p < 0.01) On
the other hand, Vogl et al. (121) detected more HCCs with
ferumoxides-enhanced MRI than with dynamic Gd-
enhanced MRI. As with Mn-DPDP, the lack of a dynamic
imaging capability limits the possibilities for lesion char-
acterization with SPIO-enhanced MRI. This problem can
be overcome with the new SPIO agent SHU 555 A (Fig.
13) or, when available, USPIO.
Some authors have proposed the possibility of a single-
visit sequential SPIO-Gd protocol to obtain better diag-
nostic confidence (122). Ward et al. (123) found that the
combination of Gd and ferumoxides in double-contrast
MRI, compared with ferumoxides-enhanced imaging
alone, led to an improvement in the diagnosis of HCC,
especially for small lesions (less than 1 cm), for which the
sensitivity for detection increased from 14% to 46%, com-
pared with larger lesions (1 cm or larger), for which the
sensitivity increased from 81% to 91% with the addition
of Gd-enhanced imaging. Post–Gd-enhanced images ob-
tained during the arterial and portal phases of enhance-
ment were essential for differentiating HCC from adjacent
fibrosis, which is the most frequent cause of false-positive
findings of SPIO-enhanced and SPIO-unenhanced images.
Pauleit et al. (124) found that for detection of small
HCCs, the sensitivity and accuracy with unenhanced and
Gd-enhanced imaging were significantly (p! 0.017) su-
perior to those with unenhanced and ferumoxides-
enhanced imaging, whereas for large HCCs the ferumox-
ides set was superior to the Gd set, although this difference
was not statistically significant. Analysis of all HCCs re-
FIG. 10. High-grade dysplastic nodule in a 56-year-old man with cirrhosis. a: TSE T2-weighted transverse MRI shows a round isointense nodule with
some slightly hyperintense areas in the right lobe (arrow). b: On precontrast T1-weighted GRE transverse images the lesion is hyperintense. During
dynamic imaging with bolus administration of Gd-BOPTA (GRE transverse T1-weighted), the lesion shows inhomogeneous enhancement in the arterial
phase (c) to become hypointense in the portal venous (d) and distribution phase (e), with a peripheral capsule. f: In the hepatobiliary phase (GRE
transverse T1-weighted) 2 hours after Gd-BOPTA injection the lesion is hyperintense.
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vealed no significant differences for Gd-enhanced and
ferumoxides-enhanced imaging (124).
Fibrolamellar HCC was first described by Edmonson
and Steiner (101). Fibrolamellar HCC is a sharply defined,
lobulated, nonencapsulated tumor, whose characteristic
microscopic features include fibrolamellar bands of colla-
gen and fibrocytes arranged in a lamellar pattern and in
delicate bands between nests of tumor cells, which often
coalesce to form a central scar (125). Typically, fibrola-
mellar HCCs occurs in a noncirrhotic liver, primarily in
young adults with no clear gender predominance (126).
On CT and MRI the majority of tumors demonstrate
hypervascularity with an inhomogeneous pattern. A cen-
tral scar is seen in about 71% of the cases with absent or
FIG. 12. Well-differentiated hepatocellular carcinoma in a patient with chronic hepatitis evaluated with Mn-DPDP. a: On precontrast T1-weighted GRE
image a isointense nodule can be seen in the right lobe (arrow). b: After Mn-DPDP administration the lesion becomes inhomogeneously hyperintense,
with a marked hyperintense eccentric focus. c: Pathologic specimen from which the histologic diagnosis was made.
FIG. 11. Hepatocellular carcinoma in a 78-year-
old woman with cirrhosis. No definite focal
lesions in liver can be seen on either TSE T2-
weighted transverse MRI (a) or precontrast T1-
weighted GRE transversal images (b). During
dynamic imaging with bolus administration of
Gd-BOPTA (GRE transverse T1-weighted), two
small hyperintense lesion can be seen in the right
lobe at the arterial phase (c). d: In the portal ve-
nous phase the bigger lesion is hypointense with a
pseudocapsule. The smaller lesion is no longer
evident. e: In the hepatobiliary phase (GRE trans-
verse T1-weighted) 2 hours after Gd-BOPTA in-
jection, both lesions are hyperintense (arrows)
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minimal contrast enhancement. Calcifications are found in
68% of lesions with CT, almost always within the central
scar, whereas hemorrhage and necrosis are rarely found.
The fibrous tissue within the scar and radial septa dem-
onstrate persistent enhancement on contrast-enhanced CT
and MRI obtained 10 to 20 minutes after contrast material
administration (125). In our experience of three cases of
fibrolamellar HCC imaged with Gd-BOPTA–enhanced
MRI, none of the tumors showed delayed enhancement 1
to 3 hours after contrast administration.
With Mn-DPDP, tumor enhancement was seen in one
of three fibrolamellar HCC cases, giving an overall iso-
intense appearance, but enhancement was not in the re-
maining two cases (125). Lymph node enhancement in
metastatic fibrolamellar carcinoma after administration of
Mn-DPDP has been reported (127). To our knowledge,
there are no reports of Fl-HCC enhancement patterns after
SPIO. Such lesions would not be expected to enhance
significantly.
Benign nonhepatocytic focal lesions
Capillary hemangiomas are rapidly filling hemangio-
mas that occur significantly more often in small heman-
giomas (42% of hemangiomas less than 1 cm in diameter)
(128). On CT and MRI, capillary hemangiomas show im-
mediate homogeneous enhancement in the arterial phase;
thus, differentiation from other hypervascular tumors is
difficult. According to various authors, up to 83% of the
smaller hemangiomas (less than 3 cm) showed isoattenu-
ation compared with the arterial system in all three phases
of enhanced scanning (Fig. 14) (129,130).
Hyperintensity on T2-weighted images has been relied
upon by some to establish the diagnosis of hemangioma,
although it must be remembered that on heavily T2-
weighted sequences with long echo delay times, high sig-
nal intensity lesions may be produced by some hypervas-
cular metastases, such as sarcoma, islet cell tumor,
pheochromocytoma, carcinoid (Fig. 15a), and renal cell
carcinoma (Fig. 16a).
During the portal venous phase of contrast enhance-
ment, capillary hemangiomas shows an attenuation
equivalent to that of the aorta. In the distribution phase,
CT or MRI hemangiomas remain hyperattenuating or hy-
perintense, whereas hypervascular metastases do not
(131). The MR findings with liver-specific contrast agents
are discussed in the section of cavernous hemangioma,
which is found in the section of focal liver lesions with
delayed persistent enhancement.
FIG. 13. Hepatocellular carcinoma in a 51-
year-old man with chronic hepatitis evaluated
with SHU 555 A. a: TSE T2-weighted trans-
verse MRI shows a round nodule in the right
lobe that is slightly hyperintense compared with
the background liver. Note the higher signal pe-
ripheral rim. b: On precontrast T1-weighted
GRE transversal images the lesion is hypoin-
tense. During dynamic imaging with bolus ad-
ministration of SH U 555 A (GRE transverse
T1-weighted), the lesion shows a slight en-
hancement in the arterial phase (c), becoming
hypointense in the portal venous phase (d). e:
TSE T2-weighted transverse MRI 10 minutes
after SH U 555 A injection. Slight homoge-
neous signal drop is observed throughout the liver parenchyma. The lesion shows a lack of contrast media uptake; thus, it appears more hyperintense
compared with the surrounding liver parenchyma.
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Malignant nonhepatocytic focal lesions
Hypervascular metastases derive from highly vascular
tumors, such as carcinoid, islet cell tumor, renal carci-
noma, thyroid carcinoma, pheochromocytoma, melanoma,
and breast carcinoma. On unenhanced images, when com-
pared with background liver tissue these lesions usually
are hypointense on T1-weighted images and slightly hy-
perintense and/or heterogeneous in SI on T2-weighted im-
ages. As mentioned previously, some hypervascular me-
tastases tend to have higher SI on T2-weighted images and
may mimic hemangiomas (Figs. 15a and 16a) (132,133).
These lesions show significant enhancement during the
arterial phase of ECF agent contrast enhancement, which
is the most important phase for lesion detection (Fig. 15c),
whereas hypovascular lesions are best imaged during the
portal phase. The equilibrium phase is best used for lesion
characterisation rather than detection, by analyzing the
pattern of enhancement and degree of contrast wash-out.
In the portovenous phase these lesions may become isoin-
tense with the normal liver parenchyma. Larger hypervas-
cular metastases receive arterial blood mainly in the pe-
riphery of the lesion than in the less perfused center and
thus shows a peripheral rim of enhancement (Fig. 16c)
(132,133).
In the portovenous phase these lesions usually show
some rapid washout, which renders them slightly lower in
density than the surrounding normal liver parenchyma. On
delayed phase the CM accumulates in the center of the
lesion because of its pooling in the extracellular fibrotic
component of the lesion, thus becoming progressively hy-
perintense to the surrounding liver parenchyma (delayed
central pooling). At the periphery of the lesion the clear-
ance of CM is faster than the normal surrounding liver
parenchyma (peripheral washout), thus giving an hypoin-
tense halo because the enhancement prevails within the
central zone of the metastasis and within the perilesional
hepatic tissue (134). The latter finding of peripheral wash-
out is specific for metastases but is a relatively uncommon
finding, as discussed later. When T2 signal intensity is
high, mimicking hemangioma, inhomogeneous signal in-
tensity on unenhanced images, early washout, delayed
central pooling, and multiple lesions are suggestive for the
metastatic nature of the lesion.
The dynamic enhancement with Gd-BOPTA–enhanced
dynamic MRI is superimposable with the patterns seen
with ECF Gd-based contrast agents. However in the late
hepatobiliary phase (about 1 hour after Gd-BOPTA injec-
tion), all metastases appear hypointense to the surrounding
hyperintense background liver parenchyma (Figs. 15e and
16e). It should be stressed that 1 hour after the injection of
FIG. 14. Capillary hemangioma in a 28-year-old
man with no history of malignancies. a: TSE T2-
weighted transverse MRI shows a small lesion in
the left lobe that is markedly hyperintense com-
pared with the background liver. The lesion is
hypointense on the precontrast T1-weighted GRE
transverse sequence b: During dynamic imaging
with bolus administration of Gd-BOPTA (VIBE
transverse T1-weighted), the lesion shows a sig-
nificant enhancement at the arterial phase (a) and
persists as slightly hyperintense in the portal ve-
nous phase (b). e: In the hepatobiliary phase
(VIBE transverse T1-weighted) 1 hour after Gd-
BOPTA injection, intense enhancement of the
liver parenchyma can be observed. The lesion is
hypointense due to the lack of contrast media up-
take on delayed imaging.
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Gd-BOPTA, some pooling of CM can be observed in the
center of the lesion, secondary to its accumulation in the
extracellular space of the lesion, thus mimicking hepato-
cytic accumulation. In such cases, it can be useful to re-
peat the sequence 2 to 3 hours. after the injection, when a
complete washout of the CM from the interstitial space
has been obtained.
After Mn-DPDP infusion, hypervascular metastatic le-
sions typically appear hypointense to the surrounding liver
parenchyma, the latter higher in signal. However, uptake
of Mn2+ after Mn-DPDP infusion also has been observed
in hepatic metastases from nonfunctioning endocrine tu-
mors of the pancreas (16).
After SPIO, there is no significant uptake of CM; thus,
the lesion appears hyperintense to the low signal intensity
of the surrounding normal liver parenchyma on T2-
weighted or T2*-weighted images. The rapid injection
possible with SHU 555 allows one to observe both dy-
namic and RES phases, thus facilitating lesion character-
ization (Fig. 17).
Among solid hypovascular liver lesions, metastases are
the main group. Hepatic metastases are the most frequent
malignancies in the liver. The incidence of hepatic metas-
tases is approximately 40% in patients with colorectal can-
cer (135). In the United States, approximately 50,000
cases of hepatic colorectal metastases are seen annually
(136). Lesion detection is size related. An accepted lower
threshold for detection is about 1 cm (137). Unfortunately,
postmortem assessment of the size of liver metastases has
shown that the ratio between metastases larger than 1 cm
and those smaller than 1 cm is approximately 1:1.6 for
metastases of colorectal adenocarcinoma and 1:4 for other
liver metastases (138). This clearly indicates that a capac-
ity to accurately detect and characterize metastases
smaller than 1 cm is necessary.
The gross morphology of liver metastases, their local-
ization, and their number show a wide range of variability
(139,140). Metastatic lesions tend to be round, but metas-
tases from colorectal adenocarcinoma larger than 3 cm
commonly have a cauliflower aspect (Figs. 18 and 19)
(141). The signal intensity of the metastases is lower than
surrounding hepatic tissue on T1-weighted images but is
higher on T2-weighted images.
Liquefactive necrosis within the metastasis increases
signal intensity on T2-weighted images, whereas coagu-
lative necrosis (142), desmoplastic reaction, or calcifica-
FIG. 15. Hypervascular metastases in a 65-
year-old woman previously operated on for il-
eal carcinoid with a OctreoScan test result
positive for hepatic secondaries. a: SE trans-
verse T2-weighted image shows a small hyper-
intense lesions in the right lobe (arrow). b:
GRE transverse T1 precontrast image. The le-
sion is homogeneously hypointense. Another
smaller lesion can be appreciated (arrow). Dur-
ing dynamic imaging with bolus administra-
tion of Gd-BOPTA (GRE transverse T1-
weighted), both lesions are homogeneously
hyperintense at arterial phase (c). d: In the por-
tal venous phase, the lesions are isointense. (e)
GRE transverse T1-weighted images obtained
2 hours after administration of Gd-BOPTA.
Both lesions are hypointense due to the lack of
contrast media uptake.
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tions (143) decrease signal intensity on T2-weighted im-
ages (Fig. 19a).
The presence of a peripheral hyperintense halo, more
than to edema, seems to have contribution srom edema as
well as marginal infiltration into adjacent liver with zones
of necrosis (142). In about 25% of colorectal hepatic me-
tastases a hypointense peripheral rim is observed in the
parenchyma around tumor nodules on T2-weighted im-
ages. The associated histopathologic changes are com-
pression of hepatic parenchyma, hepatocellular atrophy,
fibrosis, inflammation, and congested sinusoids (142).
In some cases, the production of paramagnetic sub-
stances modifies the appearance of metastases on T1-
weighted images. The melanin present in the metastases
from melanoma increases the signal intensity on T1-
weighted images. The mucin (in metastases from macro-
cystic adenocarcinoma of the pancreas or ovary) increases
the signal intensity on T1-weighted images because of the
binding of water molecules with proteinaceous macromol-
ecules, thus reducing the content of free water molecules
(140).
Dynamic MRI with ECF agents has been shown to be
equivalent to spiral CTAP for lesion detection in one study
(144). On hepatic arterial phase, metastases can show a
fleeting ring enhancement that blurs the margins of the
lesions and corresponds to a desmoplastic reaction, in-
flammatory infiltration, and vascular proliferation in the
tumor liver parenchyma margin (Fig. 19c). Enhancement
progresses centrally with concomitant peripheral washout
(Fig. 18). In the equilibrium phase (10 minutes after ad-
ministration of contrast material), some lesions show a
peripheral hypointense rim (“peripheral washout” sign;
Fig. 18d). Mafhouz et al. (134) reported that this sign was
absent in all of the benign lesions (p < 0.001), with a
sensitivity of 24.5% and a specificity of 100% in the di-
agnosis of malignancies of the liver.
After Gd-BOPTA administration, the dynamic study is
superimposable with that obtained with conventional ex-
travascular-extracellular Gd-based contrast agents. In the
hepatobiliary, phase the lesions do not show significant
enhancement because they cannot uptake the CM (3).
When there is a desmoplastic reaction to the lesion, an
accumulation in the fibrotic part can be observed, which
can remain for several hours. In these cases, observation
FIG. 16. Hypervascular metastases in a 63-
year-old woman previously operated on for re-
nal cell tumor. a: SE transverse T2-weighted
image shows a large hyperintense lesion in the
right lobe. Two others hyperintense lesion can
be seen, one in the right lobe (arrow) and the
other in segment IV (arrowhead). b: GRE
transverse T1 precontrast image. The large le-
sion is homogeneously hypointense. The other
smaller lesions are markedly hypointense.
During dynamic imaging with bolus adminis-
tration of Gd-BOPTA (GRE transverse T1-
weighted), the large lesion enhances intensely,
especially in the periphery during the arterial
phase (c). d: In the portal venous phase the
lesion is homogeneously hyperintense. The
two smaller lesions do not show contrast enhancement (cysts). e: GRE transverse T1-weighted images obtained 2 hours after administration of Gd-BOPTA.
The large lesion is hypointense because of lack of persistent contrast media (CM) uptake. The gallbladder is markedly hyperintense due to CM in the bile.
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of a peripheral hypointense halo of the lesion is highly
suggestive of the malignant nature of the lesion (Fig. 19e
and f).
After injection of Gd-EOB-DTPA, liver metastases
demonstrated inhomogeneous uptake of Gd-EOB-DTPA
during the distribution phase, with a washout effect on
delayed images at 3 minutes and the highest tumor liver
contrast seen at 20 and 45 minutes after contrast (145).
After Mn-DPDP there is an increase of the liver-to-lesion
CNR because of the lack of contrast uptake.
Colorectal metastases show a rim enhancement (Fig.
19g) that is generally more pronounced on more delayed
(24 hours after injection) images compared with images
obtained 1 hour after infusion. This rim has been postu-
lated to be due to the compression of peritumoral sinusoi-
dal spaces, with poor excretion of contrast agent and hence
early and delayed enhancement (116).
Metastases do not contain RES cells; thus. after SPIO
injection the liver metastasis CNR is improved with in-
creased lesion conspicuity and detection compared with
nonenhanced T2-weigted images (Fig. 20) (45,146,
147).
Because of the nonspecific behavior of malignant liver
lesions after SPIO injection, some authors have proposed
a dual contrast study to improve lesion characterization.
Pre-SPIO and post-SPIO injection images are obtained,
followed by bolus injection of Gd-DTPA and multiphasic
dynamic T1-weighted GRE images (124,148,149).
After injection of SPIO the quality of Gd-enhanced se-
quences is not diminished, and the same features observed
in conventional (ECF-only) dynamic studies for a variety
of lesions are valid for characterization purposes. In par-
ticular, metastases showed rim enhancement on the earlier
images with a delayed central enhancement in almost all
lesions, whereas peripheral washout was observed in
about one third of the lesions (122).
With USPIO a hyperintense rim enhancement noted in
some patients may be due to blood pool enhancement in
peripheral vessels surrounding malignant tissue observed
on T1-weighted images (54). This finding may constitute
an additional feature for characterization of metastases.
Moreover, the persistence of a T1 blood pool effect of
AMI-25 has implications for tumor differentiation be-
tween hemangiomas (which present blood pool effect) and
FIG. 17. Metastasis in a 28-year-old man pre-
viously operated on for melanoma evaluated
with SH U 555 A. a: TSE T2-weighted trans-
verse MRI shows a small lesion in the right lobe
slightly hyperintense to the surrounding paren-
chyma (arrow). b: On precontrast T1-weighted
GRE transversal images the lesion is hypoin-
tense. c: During the arterial phase of dynamic
imaging with bolus administration of SH U 555
A (GRE transverse T1-weighted), the lesion
shows a continuous rim of subtle peripheral en-
hancement. d: The lesion is slightly hypoin-
tense in the portal venous phase. e: TSE T2-
weighted transverse MRI 10 minutes after SH U
555 A injection. Slight homogeneous signal drop is observed throughout the liver parenchyma. The lesion shows a lack of contrast media uptake; thus,
it appears more hyperintense to the surrounding liver parenchyma.
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metastases, when T1-weighted gradient-echo images are
performed (150).
Focal liver lesions with delayed
persistent enhancement
In this section the focal liver lesions in which enhance-
ment is more evident during the late phase of dynamic
study are described. The most frequent lesions encountered
in this group are hemangiomas and cholangiocarcinomas.
Hemangiomas are the most common benign tumors of
the liver, with a reported incidence ranging from 1% to
20%. Hemangiomas occur more commonly in women
(female/male ratio 5:1). Although hemangiomas may be
present on patients of all ages, they are seen more com-
monly in premenopausal women (151,152). The heman-
gioma usually is well circumscribed and blood filled. It
ranges in size from a few millimeters to more than 20 cm.
Hemangiomas larger than 10 cm are designated as giant
hemangiomas (153). Hemangiomas may occur in con-
junction with FNH (15%–20%). It frequently is a solitary
tumor, although multiple hemangiomas occur in about
10% to 20% of cases (154).
On cut sections, hemangiomas almost always are het-
erogeneous with areas of fibrosis, necrosis. and cystic
change Sometimes abundant fibrous tissue completely re-
places the lesion. Calcification is rare in this tumor (less
than 10%) and can be either large and coarse, with phleb-
olith-like thrombi within the vascular channels of the hem-
FIG. 18. Metastasis in a patient previously operated on for colon carcinoma with dynamic administration of Gd-BOPTA showing peripheral washout.
a: GRE transverse T1 precontrast image. Large lesion with cauliflower aspect is homogeneously hypointense. b: During the arterial phase with bolus
administration of Gd-BOPTA (GRE transverse T1-weighted), the large lesion at shows a fleeting ring enhancement that blurs the margins of the lesions.
c: In the portal venous phase the enhancement progresses centrally. d: At the equilibrium phase a peripheral hypointense rim (“peripheral washout” sign)
can be seen.
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angioma (131,151). Microscopically it is composed of
multiple vascular channels lined by a single layer of en-
dothelial cells supported by a thin fibrous stroma.
Hemangiomas usually are asymptomatic, and results of
liver function tests are normal. Rarely patients present
with abdominal pain. Exceptionally the clinical picture is
an inflammatory syndrome of fever and leukocytosis or
thrombocytopenia and fibrinopenia or cholestasis without
jaundice. These atypical presentations sometimes are as-
sociated with intratumoral hemorrhage or thrombosis;
spontaneous rupture is distinctly rare (131). Asymptom-
atic hemangiomas should not be treated. Most hemangio-
mas can be managed conservatively.
Hepatic resection for cavernous hemangioma should be
performed only in patients with moderate-to-severe symp-
toms, complicated lesions, or both, because most benign
lesions have a good natural course. Less invasive surgical
procedures are being recommended with increasing fre-
quency for cases in which treatment of these benign tu-
mors is indicated (152,155).
On MRI, hemangiomas characteristically demonstrate
marked hyperintensity on T2-weighted images (Figs. 3a
and 21a), which may contain low-intensity areas that cor-
relate with zones of fibrosis (Fig. 22a) (156). On precon-
trast T1-weighted images, hemangioma is seen most com-
monly as a well-defined slightly hypointense mass with
FIG. 19. Metastasis in a patient previously operated on
for colon carcinoma. a: SE transverse T2-weighted im-
age shows a large lesion with cauliflower aspect inho-
mogeneously hyperintense, with a central hyperintense
area and a peripheral component that is nearly isoin-
tense. b: GRE transverse T1 precontrast image. The
lesion is hypointense with respect to the background
parenchyma and shows a darker core in an area corre-
sponding to the central hyperintense area on the T2-
weighted image. c: During the arterial phase of
dynamic imaging with bolus administration of Gd-
BOPTA (GRE transverse T1-weighted), the lesion
shows heterogeneous enhancement with a peripheral
component. d: The enhancement progresses more cen-
trally in the portal venous phase. e: In the hepatobiliary
phase 1 hour after injection of Gd-BOPTA, the lesion shows substantial but heterogeneous enhancement due to accumulation of contrast media (CM)
in the fibrotic area. f: The enhancement still can be seen 5 hours after CM injection. g: GRE transverse T1-weighted image 1 hour after Mn-DPDP
injection. The lesion is markedly hypointense due to lack of contrast uptake. A peripheral rim enhancement can be observed (arrow). h: Surgical specimen
from a segmental resection shown for correlation.
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FIG. 21. Hemangioma in a 53-year-old woman. a: SE transverse T2-weighted image shows a round hyperintense lesion in the right lobe of the liver,
which is hypointense on GRE transverse T1 precontrast image (b). During dynamic imaging with bolus administration of Gd-BOPTA (GRE transverse
T1-weighted), the lesion shows a globular peripheral enhancement, starting in the arterial phase (c) and becoming homogeneously hyperintense on the
distribution phase (d). e: SE transverse T2-weighted images 1 hour after administration of Endorem. Homogeneous signal drop is observed throughout
the liver and the lesion, which persists slightly hyperintense to the surrounding liver parenchyma. f: GRE transverse T1-weighted image 1 hour after
administration of Endorem. The hemangioma appears slightly hyperintense.
FIG. 20. Metastasis in a 55-year-old man previously operated on for colon carcinoma. FLASH T2*-weighted transverse image before (a) and after 1
hour after (b) Endorem administration. a: On unenhanced imaging a subtle, slight hyperintense lesion can be seen in the right lobe. b: After Endorem
administration a marked signal drop in the liver parenchyma can be seen, rendering the lesion clearly visible (arrow).
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lobulated borders. The pattern of “nodular” enhancement
after Gd injection was seen as highly specific for heman-
gioma (Fig. 21) compared with rim enhancement noted in
metastases (156,157).
Three enhancement patterns of hemangioma with Gd-
enhanced gradient-echo imaging have been noted: (1) im-
mediate and complete enhancement of small lesions (so-
called capillary hemangiomas; Fig. 14); (2) peripheral
nodular enhancement progressing centripetally to uniform
enhancement (Fig. 21d); and (3) peripheral nodular en-
hancement with persistent central hypointensity (Fig. 22b)
(158). Uniform enhancement throughout the lesion on de-
layed images should not be used as a criterion for diag-
nosis because this will only lower the specificity (159). In
the majority of cases the combination of T2-weighted and
serial dynamic Gd images allows a confident diagnosis of
hemangiomas (156).
On delayed liver-specific phase, after Gd-BOPTA or
Mn-DPDP hemangiomas tend to be hypointense com-
pared with the surrounding liver parenchyma (3,18). After
SPIO injection, hemangiomas often lose signal on T2-
weighted images (Figs. 3g, 21e, and 22c), whereas a sig-
nificant increase of signal intensity has been reported on
postcontrast T1-weighted images due to R1 relaxivity of
low concentrated SPIO in vascular spaces of the heman-
gioma (Figs. 3h, 21f, and 22d) (48). Within hemangiomas
the SPIO concentration is similar to that of vessels be-
cause of the high blood content of this tumor. Uptake of
FIG. 22. Atypical hemangioma in a 45-year-old man previously operated on for colon carcinoma. a: SE transverse T2-weighted image shows an
inhomogeneously hyperintense lesion in the right lobe of the liver. During dynamic imaging with bolus administration of Gd-BOPTA (GRE transverse
T1-weighted), the lesion shows a peripheral enhancement, which does not reach the center of the lesion until the distribution phase (b) and then only with
slight enhancement. c: SE transverse T2-weighted images 1 hour after administration of Endorem. Homogeneous signal drop throughout the liver and
the lesion. d: SE transverse T1-weighted image 1 hour after administration of Endorem. The hemangioma appears slightly but uniformly hyperintense.
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SPIO in hemangioma appears to be due to pooling of the
contrast agent within the vascular channels of hemangio-
mas (83). With SHU 555 A it is possible to obtain both
dynamic and RES phase imaging of hemangioma. Dy-
namic imaging shows the same morphologic features ob-
served with Gd-enhanced dynamic MRI, whereas RES
phase shows both T1 and T2 effect of SPIO.
Cholangiocellular carcinoma (CCC) is a malignant he-
patic tumor of the biliary epithelium and is the second
most common form of primary hepatic malignancy in
adults after HCC (57). It represents less than 1% of all
newly diagnosed cancers in North America and usually is
seen in the seventh decade of life with a slight male pre-
dominance (160).
Several factors have been linked etiologically to the
development of CCC, although none of the factors is evi-
dent in many patients. Cholangiocarcinoma is associated
with clonorchiasis, intrahepatic stone disease, choledochal
cyst, Caroli disease, and primary sclerosing cholangitis
(161). Most of these risk factors have in common long-
standing inflammation and injury to bile duct epithelium.
Primary sclerosing cholangitis (PSC) is commonly asso-
ciated with CCC, with as many as 10% of patients with
PSC going on to develop CCC (162). This form of cancer
sometimes occurs in the presence of cirrhosis and has been
weakly correlated to hepatis C virus infection. Mixed
hepato-cholangiocellular carcinomas have been described
(163).
Cholangiocarcinoma usually is divided into “intrahe-
patic” and “extrahepatic,” depending on the site of origin.
For the purposes of this discussion only the intrahepatic
subgroup is presented.
Intrahepatic cholangiocarcinoma (ICC) is a malignant
neoplasm arising from the epithelium of the intrahepatic
bile ducts and represents 10% of all cholangiocarcinomas.
Hilar (Klatskin) and bile duct cholangiocarcinomas ac-
count for the remaining 90% (57). This neoplasm usually
is a large firm mass. In 10% to 20% of cases there are
FIG. 23. Peripheral cholangiocarcinoma in a 70-year-old man. a: TSE transverse T2-weighted image shows a large heterogeneous, slightly hyperintense
lesion with blurred margins in the right lobe of the liver and capsular retraction (arrow). b: GRE transverse T1 precontrast image. The lesion is
homogeneously hypointense to the surrounding liver parenchyma. c: During the arterial phase of dynamic imaging with bolus administration of
Gd-BOPTA (GRE transverse T1-weighted), the lesion is homogeneously hypointense. d: In the portal venous phase, the lesion shows some enhancement
with a lace-like pattern. e: In the distribution phase, the enhancement has become clearly evident. f:GRE transverse T1-weighted images obtained 2 hours
after administration of Gd-BOPTA. Homogeneous enhancement of the liver is noted. The lesion shows accumulation of contrast media in the desmo-
plastic area, with a peripheral zone of washout.
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several satellite nodules around the main mass. On cut
section, it is characterized by the presence of large
amounts of whitish fibrous tissue. A variable amount of
central necrosis could be present within the tumor, espe-
cially if it is large. Hemorrhage is rare (164).
Microscopically the tumor is an adenocarcinoma with a
glandular appearance and cells resembling biliary epithe-
lium. Mucin and calcification sometimes can be demon-
strated. A large desmoplastic reaction is typical of chol-
angiocarcinoma. The liver parenchyma and hepatoduodenal
ligaments commonly are invaded by Klatskin tumor. Lym-
phatic metastases most commonly involve the portocaval su-
perior and posterior pancreaticoduodenal lymph nodes (165).
Clinical signs and symptoms are related to the site of
origin of the tumor. In ICC, symptoms usually are vague
until the tumor stage is far advanced and patients present
with abdominal pain and a palpable mass in the upper
abdomen. Jaundice is rarely a presenting symptom in ICC,
whereas it is common with hilar or ductal cholangiocar-
cinoma (165,166). ICC is a relatively uncommon tumor
with an insidious onset and late presentation contributing
to poor survival. Surgical resection is the only therapeutic
option. Because few patients are potentially resectable at
the time of presentation, efforts at early diagnosis and
options for adjuvant therapy are imperative. In selected
patients, complete surgical resection can be performed
safely and is associated with long-term survival. Surgical
resection provides the best survival with a good quality of
life for patients with hilar cholangiocarcinoma. Long-term
survival after resection is significantly associated with less
advanced tumor stages (165).
On MRI, ICC has a nonspecific appearance. It is isoin-
tense to hypointense on precontrast T1-weighted images.
On T2-weighted images the signal intensity of the tumor
ranges from markedly increased to mildly increased, rela-
tive to liver (Fig. 23a and b). Tumors with high fibrous
content tend to have lower signal intensity on T2-weighted
images (164,167).
FIG. 24. Hypervascular peripheral cholangiocarcinoma in a 66-year-old man. a: HASTE transverse T2-weighted image shows a small isointense lesion
with hyperintense margins in the right lobe of the liver (arrow) and capsular retraction (arrowhead). b: GRE transverse T1 precontrast image. The lesion
is homogeneously hypointense to the surrounding liver parenchyma. c: During the arterial phase of dynamic imaging with bolus administration of
Gd-BOPTA (GRE transverse T1-weighted), the lesion is hyperintense. d: In the portal venous phase, the lesion shows a persistent enhancement. e: GRE
transverse T1-weighted images obtained 2 hours after administration of Gd-BOPTA. Homogeneous enhancement of the liver is evident, and the lesion
is hypointense with slight accumulation of contrast media (CM) in the desmoplastic center. f: GRE transverse T1-weighted images obtained 1 hour after
administration of Mn-DPDP. The lesion is hypointense with slight accumulation of CM in the desmoplastic area.
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With serial dynamic ECF-Gd enhanced images, chol-
angiocarcinomas show minimal or moderate incomplete
rim of enhancement at the tumor periphery on early im-
ages, with progressive central contrast enhancement on
later images (168). As with CT, contrast enhancement
may be seen better on delayed images because of the
nature of the tumor (Fig. 23c–e) (169).
Dynamic imaging with Gd-BOPTA is similar to non-
specific vasculo-interstitial Gd-based contrast agents, but
in the hepato-biliary phase the lesion shows contrast en-
hancement in the fibrotic area (Fig. 23f). The degree of
enhancement depends on the type of cholangiocarcinoma.
Greater peripheral enhancement is noted in the early
phases in large cholangiocarcinoma, whereas greater de-
layed enhancement is noted in the fibrous core of the
“scirrhous” cholangiocarcinomas in the hepatobiliary
phase (3). Occasionally some small peripheral cholangio-
carcinomas with a large number of tumor cells and few
interstitial fibrous tissues at dynamic magnetic resonance
images reveal strong enhancement of the whole tumor on
the early phase (Fig. 24) (167), thus making difficult dif-
ferentiation from other hypervascular hepatic tumors. Pro-
longed enhancement of the tumor on late and delayed
phases of dynamic images could be of diagnostic value
(170).
After Mn-DPDP administration no significant uptake is
observed within the lesion (Fig. 24), although some pe-
ripheral rim enhancement has been observed (116), which
has been attributed to peritumoral malignant infiltration
and compression of surrounding normal liver tissue (117).
The hepatobiliary phase after liver-specific CM adds use-
ful information for identification of small satellite lesions.
Analogously, after SPIO administration, because of the
absence of Kupffer cells within the lesion, no significant
uptake is observed, and there is an increase of liver-to-
lesion contrast noise signal on T2-weighted images (Fig.
25) (171).
CONCLUSION
Use of ECF Gd-based contrast agents with dynamic
acquisitions is the predominant means of performing con-
trast-enhanced liver MRI. However, increased use of tar-
geted CM can improve the sensitivity and specificity of
MR study in the identification and characterization of fo-
cal liver lesions. As experience is gained with these
FIG. 25. Peripheral cholangiocarcinoma in a 62-year-old man. a: TSE transverse T2-weighted image shows a large hyperintense lesion in the left lobe
of the liver. b: GRE transverse T1 precontrast image. The lesion is homogeneously hypointense to the surrounding liver parenchyma. During dynamic
imaging with bolus administration of SH U 555 A (GRE transverse T1-weighted), the lesion does not show any significant enhancement in the arterial
(c) and portal venous phases (d). e: GRE transverse T1-weighted images obtained 10 minutes after administration of SH U 555 A. Slight enhancement
of the liver parenchyma at the margins of the lesion is seen. e: TSE transverse T2-weighted images obtained 10 minutes after administration of SH U
555 A. Homogenous signal drop of the liver parenchyma augments the contrast between the liver and the lesion.
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agents, new patterns of enhancement will be recognized
and new combinations of imaging strategies will emerge.
It is predicted that expertise with all of these agents will
further reduce the need for tissue sampling and allow a
better noninvasive means to triage patients with hepatic
malignancies.
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